Drugs / Pentarlandir™ UPPTA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04911777 | Aug → Dec 2021 | COVID-19 | SyneuRx International (Taiwan) Corp | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pentarlandir UPPTA | “Pentarlandir™ UPPTA is a white oral capsule (with 188 mg of UPPTA)” NCT04911777 ↗ |
| Known as | UPPTA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04911777 ↗ |